INTERNATIONAL TRADE COMMISSION

[Investigation Nos. 701–TA–772–774 and 731–TA–1756–1758 (Final)]

Crystalline Silicon Photovoltaic Cells, Whether or Not Assembled Into Modules From India, Indonesia, and Laos; Determinations

On the basis of the record [1] developed in the subject investigations, the United States International Trade Commission (''Commission'') determines, pursuant to the Tariff Act of 1930 (''the Act''), that an industry in the United States is materially injured by reason of imports of crystalline silicon photovoltaic cells, whether or not assembled into modules, from India, Indonesia, and Laos, provided for in subheadings 8541.42.00 and 8541.43.00 of the Harmonized Tariff Schedule of the United States, that have been found by the U.S. Department of Commerce (''Commerce'') to be sold in the United States at less than fair value (''LTFV''), and subsidized by the governments of India, Indonesia, and Laos.[2] [3] [4]

Background

The Commission instituted these investigations effective July 17, 2025, following receipt of petitions filed with the Commission and Commerce by the Alliance for American Solar Manufacturing and Trade.[5] The final phase of the investigations was scheduled by the Commission following notification of preliminary determinations by Commerce that imports of crystalline silicon photovoltaic cells, whether or not assembled into modules from India, Indonesia, and Laos were subsidized within the meaning of section 703(b) of the Act (19 U.S.C. 1671b(b)) and sold at LTFV within the meaning of 733(b) of the Act (19 U.S.C. 1673b(b)). Notice of the scheduling of the final phase of the Commission's investigations and of a public hearing to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the **Federal Register** on May 13, 2026 (91 FR 27078). The Commission conducted its hearing on September 9, 2026. All persons who requested the opportunity were permitted to participate.

The Commission made these determinations pursuant to §§ 705(b) and 735(b) of the Act (19 U.S.C. 1671d(b) and 19 U.S.C. 1673d(b)). It completed and filed its determinations in these investigations on November 2, 2026. The views of the Commission are contained in USITC Publication 5804 (November 2026), entitled *Crystalline Silicon Photovoltaic Cells, Whether or Not Assembled Into Modules, from India, Indonesia, and Laos: Investigation Nos. 701–TA–772–774 and 731–TA–1756–1758 (Final).*

By order of the Commission.

Issued: November 2, 2026.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2026–22565 Filed 11–4–26; 8:45 am]

BILLING CODE 7020–02–P

[1] The record is defined in § 207.2(f) of the Commission's Rules of Practice and Procedure (19 CFR 207.2(f)).

[2] 91 FR 58643, 91 FR 58647, 91 FR 58638, 91 FR 58658, 91 FR 58651, and 91 FR 58633 (September 16, 2026).

[3] Commissioner Samuel T. Negatu not participating.

[4] The Commission also finds that imports subject to Commerce's affirmative critical circumstances determinations are not likely to undermine seriously the remedial effect of the antidumping and countervailing duty orders on crystalline silicon photovoltaic cells, whether or not assembled into modules from India and Laos but are likely to undermine seriously the remedial effect of the antidumping and countervailing duty orders on crystalline silicon photovoltaic cells, whether or not assembled into modules from Indonesia.

[5] Members include Hanwha Q CELLS USA Inc., First Solar, and Mission Solar.

DEPARTMENT OF JUSTICE

Antitrust Division

United States, et al. v. OhioHealth Corporation; Amended Response to Public Comments on the Proposed Final Judgment

Notice is hereby given pursuant to the Antitrust Procedures and Penalties Act, 15 U.S.C. 16(b)–(h), that the Amended Response of Plaintiff United States to Public Comments on the Proposed Final Judgment has been filed with the United States District Court for the Southern District of Ohio, Eastern Division in *United States of America, et al.* v. *OhioHealth Corporation,* Civil Action No. 2:26-cv-207.

Copies of the Public Comments and the United States' Amended Response are available for inspection on the Antitrust Division's website at *http://www.justice.gov/atr* and at the Office of the Clerk of the United States District Court for the Southern District of Ohio. Copies of these materials may be obtained from the Antitrust Division upon request and payment of the copying fee set by Department of Justice regulations.

Suzanne Morris,

Deputy Director of Civil Enforcement Operations, Antitrust Division.

United States District Court for the Southern District of Ohio Eastern Division

UNITED STATES OF AMERICA and STATE OF OHIO, Plaintiffs, v. OHIOHEALTH CORPORATION, Defendant.
Case No. 2:26–cv–207
Judge Algenon L. Marbley
Magistrate Judge S. Courter M. Shimeall

Amended Response of Plaintiff United States to Public Comments on the Proposed Final Judgment

Pursuant to the Antitrust Procedures and Penalties Act, 15 U.S.C. 16(b)–(h) (the ''Tunney Act'' or ''APPA''), the United States submits this amended response to the public comments it received regarding the proposed Final Judgment in this case. The United States received four comments about the proposed remedy, which are summarized and addressed below and attached as Exhibit A. This is an amended response to the United States' Response to Public Comments on the Proposed Final Judgment (''Response to Comments''), filed on October 20, 2026. (Dkt. 34). The United States has amended its response to address a comment that had been inadvertently omitted from its initial response. Other than this paragraph, references to the number of comments received, and the addition of the comment to Exhibit A, the only changes from the initial Response to Comments are on pages 12–13. After careful consideration of the submitted comments, the United States continues to believe that the proposed Final Judgment is in the public interest because it will provide an effective and appropriate remedy for the antitrust violations the Complaint alleged.

Specifically, the proposed Final Judgment will protect competition by, among other things, voiding the anticompetitive steering and transparency restrictions, prohibiting OhioHealth Corporation (''OhioHealth'') from seeking or obtaining such provisions in the future, and prohibiting OhioHealth from penalizing payors that engage (or are planning to engage) in steering, offer steered plans, or provide price transparency to their members.

After this response has been published in the **Federal Register**, pursuant to 15 U.S.C. 16(d), the United States will move that the Court enter the proposed Final Judgment.